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Dupilumab is the first biologic registered for the treatment
of atopic dermatitis (AD). We report a case of acute-onset
monoarthritis of the ankle and generalized polyarthralgia
in a 38-year-old woman with AD, shortly after starting
dupilumab. Methotrexate (MTX) therapy for AD had been
discontinued 1 week before start of dupilumab treatment
because of decreasing effectiveness. Four weeks after
starting dupilumab, the patient reported improvement of
her eczema; however, she also reported severe joint pain
and morning stiffness in one ankle, which gradually
spread to her knees, hips and elbows. These problems
started a few days after the first dupilumab injection. She
had not contacted us earlier because she was relieved by
the rapid decrease in itch complaints. There was no his-
tory of previous joint pain and no family history of rheu-
matic diseases, and the patient’s medical history was not
contributory.
Rheumatological examination revealed tenderness of
the wrists, knees and ankles. The right ankle was slightly
swollen and warm. Laboratory investigations showed
increases in inflammatory markers: C-reactive protein
33 mg/L (normal value < 10 mg/L) and erythrocyte
sedimentation rate 63 mm/h (0–20 mm/h). Additional
tests including serology screens for parvovirus B19,
Epstein–Barr virus, Chlamydia trachomatis and Streptococ-
cus were all negative.
Radiograph of the right ankle showed swollen tissue,
without erosions or osteoarthritis.
Monoarthritis of the right ankle and inflammatory pol-
yarthralgia as an adverse drug reaction to dupilumab
were suspected, and dupilumab treatment was discontin-
ued. The patient was started on a 1-month course of cele-
coxib 200 mg twice daily and prednisolone 15 mg daily
for the joint pain, following which the arthritis and
arthralgia disappeared. Six weeks after discontinuation of
dupilumab, MTX (20 mg weekly, subcutaneously) was
started because the patient’s eczema flared. After
2 months, her eczema was controlled and the inflamma-
tory markers had decreased.
The differential diagnosis included adverse drug reaction
(ADR), serum sickness(-like reaction) [SS(LR)], peripheral
spondyloarthropathy (SpA), and rheumatoid arthritis
(RA). We considered ADR because of the clear timeline
with onset of joint pain after first administration of dupilu-
mab.1 To date, two cases of SS(LR) during dupilumab
treatment have been reported. However, our patient denied
the hallmark complaints of SS(LR), including fever, malaise
and urticarial eruption, and the rapid onset of joint pain
was not typical for SS(LR).2 RA and SpA were also consid-
ered. It has been suggested that patients with AD may
have a higher risk of developing RA.3 In addition, dupilu-
mab decreases levels of interleukin (IL)-4, which poten-
tially can increase levels of tumour necrosis factor-a and
IL-6, which are important inflammatory cytokines in the
pathogenesis of RA.4 However, our patient did not have
rheumatoid factor or anti-citrullinated protein antibodies,
nor did she meet the RA or SpA criteria.5
As a result of the multiple drugs the patient received
after discontinuation of dupilumab, it is difficult to assess
whether the problems resolved spontaneously or as a
result of the drugs that were administered. Furthermore,
the previous use of MTX could also have masked the
presence of possible pre-existing arthralgia. To our knowl-
edge, this ADR has not been reported previously, and we
hope this report will raise awareness of the potential for
arthritis and arthralgia during dupilumab treatment.
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